Abstract |
In 1981, Inanaga et al reported on the efficacy of DN-1417 (a TRH analog) in the treatment of degenerative myoclonus epilepsy and other forms of intractable epilepsy. Following this report, we studied the efficacy and safety of DN-1417 treatment in 10 intractable epileptic children ranging in age from 6 months to 11 years (mean 4 years), including 7 with Lennox syndrome (LS), 2 with West syndrome (WS) and 1 with degenerative myoclonus epilepsy (DME). The daily dose was from 0.02 to 0.05 mg/kg, initially, and then was increased to 0.05 mg/kg. Complete control of seizures was achieved in 2 patients with LS, a 50% or greater decrease in seizure frequency was observed in one patient each with LS and DME and a less than 50% decrease in 1 with LS and 2 with WS. There was no change in 2 LS cases, and 1 LS case became worse. Activation of psychic activities, such as psychomotor activity, facial expression and motivation, was also noted in 7 of the 10 patients. Furthermore, improvement of motor function was noted in 5 patients. Electroencephalographic abnormalities improved in 2 completely seizure free patients with LS in which EEG ameliorated along with clinical seizure control.
|
Authors | T Matsuishi, E Yano, K Inanaga, K Terasawa, O Ishihara, Y Shiotsuki, Y Katafuchi, N Aoki, F Yamashita |
Journal | Brain & development
(Brain Dev)
Vol. 5
Issue 4
Pg. 421-8
( 1983)
ISSN: 0387-7604 [Print] Netherlands |
PMID | 6416101
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Anticonvulsants
- Thyrotropin-Releasing Hormone
- DN 1417
|
Topics |
- Anticonvulsants
- Child
- Child, Preschool
- Drug Therapy, Combination
- Electroencephalography
- Epilepsies, Myoclonic
(drug therapy)
- Epilepsy
(drug therapy)
- Female
- Humans
- Infant
- Male
- Pilot Projects
- Spasms, Infantile
(drug therapy)
- Syndrome
- Thyrotropin-Releasing Hormone
(administration & dosage, analogs & derivatives, therapeutic use)
|